Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617000620325
Ethics application status
Approved
Date submitted
13/04/2017
Date registered
1/05/2017
Date last updated
1/05/2017
Type of registration
Prospectively registered

Titles & IDs
Public title
A descriptive study on prediction of myopic progression in Australian population
Scientific title
Peripheral refractive error profile and optic disc parameters in refractive error groups
Secondary ID [1] 291698 0
CRTC-2016-03

Clinical Research Trials Centre (CRTC) of the Brien Holden Vision Institute in Sydney
Universal Trial Number (UTN)
U1111-1195-4822
Trial acronym
Linked study record
Not applicable

Health condition
Health condition(s) or problem(s) studied:
Myopia 302868 0
Hyperopia 302910 0
Condition category
Condition code
Eye 302347 302347 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Diagnostic instruments will be used to measure parameters like refractive status of the eye and posterior surface of the eye in detail (retina and optic nerve head),
3 repeat measurements will be obtained from the instruments used to analyze the peripheral refraction Brien Holden vision Institute (BHVI) eye mapper and Shin Nippon Auto Refractor. The order of testing with these 2 instruments will be randomized .
This will be a single examiner study.
Study location Brien Holden Clinical Research and Trial Centre
Duration of this single visit study will be 60 to 90 minutes
The entire study is planned to be completed within 6 to 9 months of the study period
Intervention code [1] 297831 0
Diagnosis / Prognosis
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 301769 0
Peripheral refraction profile will be assessed using BHVI (Brien Holden Vision Institute)Eye Mapper and Shin Nippon Autorefractor
Timepoint [1] 301769 0
The duration of testing of the above mentioned values may extend from 15- 20 minutes. The entire visit of the participant is scheduled for 60 to 90 minutes.
Primary outcome [2] 301885 0
The posterior surface of the eye (retinal and choroid layer ) measurements will be obtained using Optical Coherence Tomography
Timepoint [2] 301885 0
The duration of testing of the above mentioned values may extend from 10- 15 minutes. The entire visit of the participant is scheduled for 60 to 90 minutes.
Primary outcome [3] 301912 0
Optic nerve head measurements will be obtained using Optical Coherence Tomography
Timepoint [3] 301912 0
The duration of testing of the above mentioned values may take 5 minutes or less
Secondary outcome [1] 333804 0
The optic disc tilt and torsion measurements will be performed during the optic nerve head measurements are acquired as a primary outcome. Optic disc tilt and torsion are composite secondary outcomes. These measurement obtained using the Optical Coherence Tomography will be compared between different refractive groups such as myopia, hyperopia and emmetropia. Multiple logistic regressions will be used to analyze differences between these values.
Timepoint [1] 333804 0
These measurements obtained while acquiring the primary outcome values itself. However the analyses will be performed as a secondary outcome.
Secondary outcome [2] 334192 0
As a secondary outcome repeatability of the 2 instruments Shin Nippon Auto-refractor and BHVI Eye Mapper will be tested. Peripheral refraction values between 2 instruments (BHVI EYe mapper and Shin Nippon Auto Refarctor will be compared between instruments using paired t-test. The within-patient standard deviation from the 3 repeats will be compared between instruments using Levene's test for equality of variance.
Timepoint [2] 334192 0
These measurements obtained while acquiring the primary outcome values itself. However the analyses will be performed as a secondary outcome.

Eligibility
Key inclusion criteria
Healthy participants enrolled in the trial must be male or female aged between 18- 39 years, must have provided an informed consent, can be an emmetrope, hyperope or myopia , be willing to comply with clinical trial visit schedule as directed by the investigator, have ocular health findings considered to be “normal” and no anterior segment or posterior segment condition other than refractive error, have best corrected visual acuity to at least 6/9.5 or better in each eye with spectacles or contact lenses, have clear media for obtaining refractive error measurements and optic disc images
Minimum age
18 Years
Maximum age
39 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Participants enrolled in the trial must not have astigmatism >/= 0.75 , should not be aged 40 years or older, should not have a history of any systemic diseases including diabetes, hypertension, cardiac problems etc, any refractive or ocular surgeries, using orthokeratology lenss, any other ocular pathology, ocular hypertension or glaucoma in either eye and intra ocular pressure >/= 21 mm of Hg

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Type of endpoint/s
Statistical methods / analysis
Since, there are no studies similar to this available in the literature to the best of my knowledge, a pilot study will be calculated and a post hoc power analysis will be performed later to analyse the power of the study

Kolmogorov-Smirnov test will be applied to assess the normality of data distribution. Descriptive statistics of the data will be analyzed depending on the type of distribution of the data. On achieving normality, the data set will be described using mean and standard deviation. If the data set is not normally distributed, then median and range will be used to describe the data.The within-patient standard deviation from the 3 repeats will be compared between instruments using Levene's test for equality of variance. .

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
3/05/2017
Actual
Date of last participant enrolment
Anticipated
31/07/2017
Actual
Date of last data collection
Anticipated
31/07/2017
Actual
Sample size
Target
60
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 296196 0
Other
Name [1] 296196 0
Brien Holden Vision Institute
Country [1] 296196 0
Australia
Primary sponsor type
Other
Name
Brien Holden Vision Institute
Address
Level 5, North Wing, Rupert Myers Building, Gate 14 Barker Street, University of New South Wales, UNSW NSW 2052
Country
Australia
Secondary sponsor category [1] 295107 0
None
Name [1] 295107 0
Address [1] 295107 0
Country [1] 295107 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 297437 0
Human Research Ethics Committee (HREC) The University of New South Wales
Ethics committee address [1] 297437 0
Ethics committee country [1] 297437 0
Australia
Date submitted for ethics approval [1] 297437 0
16/09/2016
Approval date [1] 297437 0
02/11/2016
Ethics approval number [1] 297437 0
HC16815

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 74038 0
A/Prof Padmaja Sankaridurg
Address 74038 0
Level 4, North Wing, Rupert Myers Building, Gate 14 Barker Street, University of New South Wales, UNSW NSW 2052
Country 74038 0
Australia
Phone 74038 0
+61 2 9385 7485
Fax 74038 0
Email 74038 0
[email protected]
Contact person for public queries
Name 74039 0
Padmaja Sankaridurg
Address 74039 0
Level 4, North Wing, Rupert Myers Building, Gate 14 Barker Street, University of New South Wales, UNSW NSW 2052
Country 74039 0
Australia
Phone 74039 0
+61 2 9385 7485
Fax 74039 0
Email 74039 0
[email protected]
Contact person for scientific queries
Name 74040 0
Padmaja Sankaridurg
Address 74040 0
Level 4, North Wing, Rupert Myers Building, Gate 14 Barker Street, University of New South Wales, UNSW NSW 2052
Country 74040 0
Australia
Phone 74040 0
+61 2 9385 7485
Fax 74040 0
Email 74040 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.